文献速递腹部MR

肝细胞腺瘤在肝胆期呈等或高信号并不总对应肝特异性对比剂摄取:对肿瘤亚型分型的重要性

Iso- or hyperintensity of hepatocellular adenomas on hepatobiliary phase does not always correspond to hepatospecific contrast-agent uptake: importance for tumor subtyping.
PubMed 文献 · Eur Radiol · 2019-04-01

这项双中心回顾性研究纳入2009至2017年经组织学确诊并分型的肝细胞腺瘤患者,均行Gd-BOPTA增强MRI肝胆期检查且病灶呈等或高信号。24个病灶中18个(75%)的肝脏-病灶对比增强率(LLCER)<0%,其中94%在增强前T1WI呈高信号并伴背景肝脂肪变;6个(25%)LLCER≥0%者均为β-catenin型。LLCER≥1.6%诊断β-catenin型肝细胞腺瘤的敏感度为86%、特异度为100%。

要点

  • 肝胆期等或高信号不等于肝特异性对比剂高摄取,需用LLCER定量区分。
  • 炎性型肝细胞腺瘤多因增强前T1WI高信号合并肝脂肪变而表现等或高信号。
  • LLCER≥1.6%诊断β-catenin型肝细胞腺瘤敏感度86%、特异度100%。

核心结论

  • 肝细胞腺瘤在肝胆期呈等或高信号并不必然对应肝特异性对比剂摄取增加,炎性型的高信号多由增强前T1WI高信号及背景肝脂肪变解释,而β-catenin型可表现为对比剂摄取增高。

研究设计与样本

  • 双中心回顾性研究,纳入2009至2017年经组织学确诊并分型、行Gd-BOPTA增强MRI肝胆期检查且病灶呈等或高信号的肝细胞腺瘤患者,共24个病灶。

关键影像表现/征象

  • 24个肝胆期等或高信号病灶中17个为炎性型肝细胞腺瘤、7个为β-catenin型肝细胞腺瘤。
  • 18个病灶(75%,17个炎性型与1个β-catenin型)的LLCER<0%(中位数-13.6%,第1组),其中94%在增强前T1WI呈高信号并伴背景肝脂肪变。
  • 6个病灶(25%)LLCER≥0%(中位数2.9%,第2组),均为β-catenin型肝细胞腺瘤。

诊断标准与关键数值

  • LLCER≥1.6%诊断β-catenin型肝细胞腺瘤的敏感度为86%、特异度为100%。
  • LLCER<0%定义为第1组,LLCER≥0%定义为第2组,用于区分肝胆期等或高信号肝细胞腺瘤的对比剂摄取情况。

临床应用与阅片要点

  • 阅片时对肝胆期呈等或高信号的肝细胞腺瘤应结合增强前T1WI信号及背景肝脂肪变判断,避免将等或高信号直接视为肝特异性对比剂摄取增高。
  • 定量LLCER有助于区分炎性型与β-catenin型肝细胞腺瘤,LLCER≥1.6%时提示β-catenin型。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: This study was conducted in order to evaluate if iso- or hyperintensity of HCAs on HBP is systematically related to a high uptake of hepatospecific contrast agent, using a quantitative approach.

METHODS: This bicentric retrospective study included all patients with histologically confirmed and subtyped HCA from 2009 to 2017 who underwent MRI with HBP after Gd-BOPTA injection and who showed iso- or hyperintensity on HBP. The signal intensity of tumors on pre- and postcontrast images and the presence of hepatic steatosis were noted. Contrast uptake on HBP was quantified using the liver-to-lesion contrast enhancement ratio (LLCER) and compared between HCA subtypes (Wilcoxon signed-rank test). Categorical variables were compared using chi-square tests.

RESULTS: Twenty-four HCAs showed iso- or hyperintensity on HBP, specifically 17 inflammatory (IHCAs) and 7 β-catenin HCAs (BHCAs). Eighteen HCAs (75%) (17 IHCAs and 1 BHCAs) had a LLCER < 0% (median - 13.6%, group 1), of which 94% were hyperintense on precontrast T1-W images, with background hepatic steatosis. Six HCAs (25%) had LLCER ≥ 0% (median 2.9%, group 2), and all were BHCAs. A LLCER ≥ 1.6% was associated with the diagnosis of BHCA with a sensitivity of 86% and a specificity of 100%.

CONCLUSION: In conclusion, iso- or hyperintensity of hepatocellular adenomas on HBP does not necessarily correspond to an increased hepatospecific contrast-agent uptake. In IHCA, tumor hyperintensity on precontrast images and the underlying steatosis likely explain such iso- or hyperintensity, which do show reduced HBP contrast-agent uptake. On the other hand, marked contrast uptake can be observed, especially in BHCA.

KEY POINTS: • Iso- or hyperintensity on HBP does not necessarily reflect a high uptake of hepatospecific contrast agent. • Discrepancies between qualitative signal intensity and quantitative hepatospecific contrast uptake can be explained in IHCA by a combination of tumor hyperintensity on precontrast images and underlying hepatic steatosis. • In BHCA, iso- or hyperintensity on HBP does actually correspond to a greater contrast uptake than that of the liver, demonstrated by an increased lesion-to-liver contrast enhancement ratio (LLCER).

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Reizine E, Ronot M, Pigneur F, et al. Iso- or hyperintensity of hepatocellular adenomas on hepatobiliary phase does not always correspond to hepatospecific contrast-agent uptake: importance for tumor subtyping. Eur Radiol. 2019. PMID: 30937584. doi:10.1007/s00330-019-06150-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。